T he treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for patients ...

AIIMS researchers claim to have made significant progress in developing chimeric antigen receptor (CAR) T-cell therapy, ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.

Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma ...

The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood ...

A study by Memorial Sloan Kettering Cancer Center revealed that a high-fiber, plant-based diet may delay the progression to ...

Panelist discusses how pivotal studies led to the approval of teclistamab in patients with less refractory multiple myeloma; ...

SAN DIEGO — The multiple myeloma (MM) drug daratumumab (Darzalex), an anti-CD38 monoclonal antibody, dramatically reduced ...

A retrospective analysis presented at the American Society of Hematology annual meeting looked at multiple myeloma patients' ...

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio's ...

an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). The new drug is one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...